Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 70. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Direct-to-consumer services: improving access to care for people with diabetes and obesity840
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale740
South Africa to produce insulin for Africa in 2024708
World Health Assembly ratifies first global diabetes targets537
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2521
Better testing and labelling of drugs for people with obesity520
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98477
Anand Hardikar: a scientific nomad searching for the truth467
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality448
Reassessing driving safety in diabetes446
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?383
Implications of technology guidelines for low-income and middle-income countries330
A framework for improving diabetes care in humanitarian emergencies256
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p239
What's preventing us from curbing the obesity crisis?216
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial204
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice189
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity184
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial179
Artificial intelligence and diabetes: time for action and caution171
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions171
Type 1 diabetes screening: need for ethical, equity, and health systems perspective165
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials161
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial159
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study154
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7144
What does renal failure teach us about our National Health System?144
Childhood obesity: a growing pandemic143
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history142
The role of nurses in diabetes care: challenges and opportunities142
Cardiovascular mortality trends among people with and without diabetes140
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials137
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X137
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss136
A roadmap for integrating mental health and diabetes services127
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin116
Healthy weight for the next generation's health in China110
Challenging diabetes stigma starts and ends with all of us105
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses104
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply103
The uncomfortable truth about kidney disease in type 1 diabetes103
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing101
The changing character of diabetes complications101
Jennifer Manne-Goehler: at the crossroads of pandemics95
The urgent need for a diabetes data rights charter94
Lebanon: insulin out of reach after subsidies lifted94
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial93
Putting wellbeing at the core of diabetes care90
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England89
Glycaemic index as part of the diabetes prevention strategy89
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement89
The promise and hope of GLP-1 receptor agonists88
Explaining the high rate of progression from prediabetes to type 2 diabetes in China88
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study85
Rising diabetes diagnosis in long COVID84
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis83
Understanding the mechanism of prediabetes remission in young people83
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 202083
CONCEPTT to care: the science of implementation in diabetes care83
Homing in on the causes of male infertility82
Women in diabetes research: stepping towards equity79
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1778
Diabetes: knowing your risk matters78
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction74
Gender equality: timely and timeless74
Improving HbA1c levels with advanced hybrid closed-loop therapy74
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–8373
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–1371
Is it time to re-assess the development of thyroid function reference ranges?70
Blood pressure control according to type 2 diabetes status70
0.11976599693298